or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    PRLD F Prelude Therapeutics Incorporated 0.57
    ALLR F Allarity Therapeutics, Inc. 5.88
    NTBL F Notable Labs, Ltd. 0.00
    BBIO F BridgeBio Pharma, Inc. 0.87
    CRIS F Curis, Inc. 10.81
    COGT D Cogent Biosciences, Inc. -1.10
    DAWN D Day One Biopharmaceuticals, Inc. -2.06
    ELVN D Enliven Therapeutics, Inc. -0.08
    PBYI C Puma Biotechnology Inc 2.11
    AVBP C ArriVent BioPharma, Inc. -2.99
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Tyrosine Kinase Biopharmaceutical Tyrosine Kinase Receptors Enzymes Non Small Cell Lung Cancer Solid Tumors Biotechnology Breast Cancer Cancer Treatment Chronic Myeloid Leukemia Drugs Her2 Lung Cancer Lymphoma Orphan Drug Phosphoinositide 3 Kinase Inhibitor Signal Transduction Small Cell Lung Cancer Treatment Of Breast Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 12.32
    CANC D Tema Oncology ETF 11.33
    CNCR F Loncar Cancer Immunotherapy ETF 8.33
    PBE D PowerShares Dynamic Biotech & Genome 6.77
    BBP C BioShares Biotechnology Products Fund 5.35
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare CNCR to PBE Compare IDNA to BBP Compare IDNA to PBE

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        Nov 21 BBIO Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
        Nov 21 PBYI PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
        Nov 21 PBYI Puma commences Phase II trial of alisertib for breast cancer treatment
        Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
        Nov 20 PBYI Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 DAWN Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
        Nov 18 ALLR Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Tyrosine Kinase Tyrosine Kinase Receptors Achondroplasia Acute Myeloid Leukemia Amyloid Amyloidosis Biopharmaceutical Blastoma Cancer Treatment Cardiomyopathy Chronic Myeloid Leukemia Clinical Development Congenital Adrenal Hyperplasia Doxorubicin Drugs Enzymes Familial Amyloid Polyneuropathy Fibroblast Growth Factor Receptor Glioblastoma
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags